Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Inclusion Criteria: * Histologically confirmed ovarian, peritoneal or fallopian tube cancer that has recurred following a platinum-based regimen used at initial diagnosis * Measurable disease * Estimated life expectancy greater than 16 weeks * Normal organ and marrow function * Evidence of non-childbearing status for women of childbearing potential * Able to swallow oral medication Exclusion Criteria: * Pregnant or breastfeeding * Prior PARP inhibitor use for another cancer such as breast cancer * Receiving any other study agents or any other anti-cancer treatment * Known brain metastases * History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive hear failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * History of a different malignancy unless disease-free for at least 5 years * Currently experiencing seizures or currently being treated with any anti-epileptic for seizures * Human immunodeficiency virus (HIV) positive on combination antiretroviral therapy * Presence of gastrointestinal disorders that, in the investigator's opinion, are likely to interfere with the absorption of olaparib, or with the patient's ability to take regular oral medication